Sponsored
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Sponsored
In this video, Dr Goy discusses recent innovations in the treatment of patients with MCL.
Sponsored
Michael Morse, MD, FACP, MHS, discusses the role that microsatellite stability (MSS) or microsatellite instability (MSI) plays in metastatic CRC.
Sponsored
Ryan Corcoran, MD, PhD, discusses the characterization of BRAF mutations and the evolving treatment landscape for patients with BRAF/RAS mutations.
At the annual Miami Breast Cancer Conference, Kelly Hunt, MD, discussed the use of neoadjuvant endocrine therapy for patients with breast cancer.
Anees Chagpar, MD, discusses her presentation on neoadjuvant chemo for clinically node-negative (cN0) breast cancer that took place at the annual Miami Breast Cancer Conference.
Anees Chagpar, MD, highlights notable research and presentations from the annual Miami Breast Cancer Conference.
Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.
Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.
Sponsored
In this video, Christina Wu, MD, discusses HER2 in patients with metastatic CRC.
Stay in the know.
OncNet Newsletter